Cavli Wireless All Set to Introduce the 5G RedCap CQM220 Cellular IoT Module at Embedded World 2024
26.3.2024 12:20:00 EET | Business Wire | Press release
Cavli Wireless, a pioneer in the IoT solutions landscape, is all set to announce its flagship 5G RedCap CQM220 Cellular IoT Module at Embedded World 2024. The event, held at the NürnbergMesse GmbH, Nürnberg, Germany, from April 9 to 11 in Hall 3, Booth 3-311. Embedded World event is known for being the largest trade fair for Embedded technology, showcasing the latest and greatest in electronic systems, distributed intelligence, IoT, energy efficiency, and more. The event represents the premier stage for global innovators like Cavli Wireless to showcase the innovative CQM220 to the world.
The CQM220 is the flagship 5G RedCap cellular IoT module from Cavli Wireless, compatible with 3GPP release 17 standards, specifically designed for advanced IoT and M2M applications. It delivers robust data bandwidth, reaching up to 226Mbps in downlink and 121Mbps in uplink, facilitating rapid and efficient data transfer. Available in LGA, PCIe Gen2, and M.2 form factors, the CQM220 ensures broad compatibility and flexibility across various industrial applications. Its optional integrated eSIM offers global connectivity through the Cavli Hubble Device and Connectivity management platform, making it a versatile solution for international deployment.
Moreover, the CQM220's optional integrated GNSS feature positions it as an ideal candidate for precise tracking applications, essential in sectors like Asset Tracking and Vehicular Telemetry Systems. Accompanied by a Linux-based OpenSDK, the module allows for application-specific coding directly on the device, eliminating the need for an external host MCU. This capability, combined with its high data throughput and global operability, makes the CQM220 an optimal choice for next-generation applications that demand speed, accuracy, and worldwide functionality.
The CQM220 module is set to supercharge a range of industries with its advanced connectivity. In Industry 4.0, the module's high data throughput, and integrated GNSS make it a linchpin for smart factories, facilitating real-time monitoring and control of machinery, and predictive maintenance, thereby enhancing efficiency and reducing downtime. For Smart City initiatives, the CQM220's global connectivity and robust bandwidth support the deployment of smart grids, intelligent transportation systems, and public safety networks, contributing to more efficient and responsive urban environments. In asset tracking, the precision of the integrated GNSS and the module's widespread connectivity ensure accurate, real-time location tracking of goods and equipment across borders, which is crucial for logistics, fleet management, and theft prevention. Across these applications, the CQM220 empowers industries to harness the full potential of seamless global connectivity, driving innovation and operational excellence.
The Cavli Hubble Stack further enhances the capabilities of the CQM220 by introducing remote diagnosis, monitoring, and debugging of the module through Hubble Lens, an advanced component of the Cavli Hubble IoT connectivity & modem management platform. This feature eliminates the necessity for physical intervention, simplifying the expansion of IoT solutions. Through strategic alliances with operators worldwide, Cavli has established a substantial presence, delivering unparalleled connectivity solutions that set new standards in service quality and cost-effectiveness.
John Mathew, the CEO and the Chief Technology Architect of Cavli Wireless, remarked, "Unveiling the CQM220 at Embedded World 2024 marks a pivotal point for our company. Our continuous commitment to superior performance and creativity in the field of intelligent cellular connections has culminated in the creation of this durable 5G RedCap module. It is characterized by its dependability, effectiveness, and the ability to provide uninterrupted connectivity worldwide. These features are the core aspects of the CQM220 and serve to set apart both the product and Cavli Wireless in the bustling market."
With the unveiling of the CQM220 at Embedded World 2024, Cavli Wireless reiterates its dedication to providing cost-effective, uninterrupted, and superior cellular IoT solutions. We encourage you to engage with our solution specialists to explore the ways the CQM220 can enhance your upcoming project. Embark on your path to dependable and effective connectivity with Cavli.
About Cavli Wireless
Cavli Wireless is a cellular IoT module manufacturer that combines IoT connectivity and data management into one platform. Cavli designs and manufactures industrial-grade cellular IoT smart modules that improve equipment reliability and expedite application development processes. Cavli's smart cellular modules are equipped with global cellular connectivity through integrated eSIM functionality that provides users with affordable global data pricing, simplified device management, and centralized subscription management through the proprietary cloud-based platform Cavli Hubble.
About Embedded World
The Embedded World Exhibition & Conference is a global platform for the embedded systems community, where professionals from around the world can connect and share knowledge. The event offers insights into the entire world of embedded systems, including hardware, software, tools, and services. It features a high-quality transfer of knowledge through top-class speakers, expert panels, and exhibitor forums.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240326234488/en/
Contact information
Shariq Jalaluddin, Manager - Corporate Marketing
Cavli Wireless
shariq.j@cavliwireless.com
+91-6282917279
https://www.cavliwireless.com/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom